申请人:Qian Wei
公开号:US20140206664A1
公开(公告)日:2014-07-24
Heterocycle amino alkyloxy substituted quinazoline derivatives as represented by the structural Formula (I) and pharmaceutically acceptable salts thereof, capable of inhibiting the activity of receptor tyrosine kinase EGFR, and being used to treat cancers related to the expression of the receptor tyrosine kinase of the ErbB family are provided.
本发明提供了异环氨基烷氧基取代的喹唑啉衍生物,其结构式表示为(I),以及其药学上可接受的盐,能够抑制受体酪氨酸激酶EGFR的活性,并用于治疗与ErbB家族受体酪氨酸激酶表达相关的癌症。